These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 26415921)

  • 1. [Castleman's disease: Rapid desensitization for hypersensitivity reaction to rituximab].
    Boin C; Lambert S; Thomann P; Aujoulat O; Kieffer P
    Rev Med Interne; 2016 Jun; 37(6):433-6. PubMed ID: 26415921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desensitization to rituximab in a multidisciplinary setting.
    Amorós-Reboredo P; Sánchez-López J; Bastida-Fernández C; do Pazo-Oubiña F; Borràs-Maixenchs N; Giné E; Valero A; Creus-Baró N
    Int J Clin Pharm; 2015 Oct; 37(5):744-8. PubMed ID: 25999014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab Hypersensitivity: Evaluation, Desensitization, and Potential Mechanisms.
    Wong JT; Long A
    J Allergy Clin Immunol Pract; 2017; 5(6):1564-1571. PubMed ID: 29122155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment.
    Brennan PJ; Rodriguez Bouza T; Hsu FI; Sloane DE; Castells MC
    J Allergy Clin Immunol; 2009 Dec; 124(6):1259-66. PubMed ID: 19910036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presentation and management of the delayed type of hypersensitivity reaction with bendamustine.
    Shikdar S; Totton D; Turco T; Rachshtut M
    Anticancer Drugs; 2018 Sep; 29(8):814-816. PubMed ID: 29877929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab desensitization in three patients with severe rituximab allergy.
    Öztürk E; Özyiğit LP; Öztürk AB; Akay MO; Çetiner M; Ferhanoğlu B
    Curr Probl Cancer; 2017; 41(5):349-354. PubMed ID: 28860080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicentric Castleman's disease masquerading as HIV-related lymphoma.
    Dayyani F; Pantanowitz L; Sandridge TG; Sullivan RJ; Dezube BJ
    Am J Med Sci; 2007 Oct; 334(4):317-9. PubMed ID: 18030193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicentric Castleman's disease & HIV infection.
    Cotter A; Lambert J; O'Gorman P
    Ir Med J; 2009 Oct; 102(9):294-5. PubMed ID: 19902650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid Drug Desensitization With Rituximab in 24 Cases: A Single-Center Experience.
    Görgülü B; Seval GC; Kendirlinan R; Toprak SK; Özcan M; Bavbek S
    J Investig Allergol Clin Immunol; 2019; 29(6):468-470. PubMed ID: 31530515
    [No Abstract]   [Full Text] [Related]  

  • 10. [Efficacy of rituximab for TAFRO syndrome, a variant type of multicentric Castleman's disease].
    Ozawa T; Kosugi S; Kito M; Onishi M; Kida T; Nakata S; Take H; Katagiri S
    Rinsho Ketsueki; 2014 Mar; 55(3):350-5. PubMed ID: 24681940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desensitisation overcomes rituximab- and tocilizumab-related immediate hypersensitivity in childhood.
    Demir S; Soyer O; Bilginer Y; Sag E; Sahiner UM; Buyuktiryaki B; Sekerel BE; Ozen S
    Clin Exp Rheumatol; 2020; 38(3):552-557. PubMed ID: 31820716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vinblastine, rituximab and HAART, treatment of an HIV -positive patient with multicentric Castleman's disease.
    van Aalderen MC; Brinkman K; van den Berk GE; Terpstra WE
    Neth J Med; 2010 Feb; 68(2):87-90. PubMed ID: 20167961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypersensitivity reactions to rituximab: 53 successful desensitizations in 7 patients with severe, near-fatal reactions.
    Lebel E; Ben-Yehuda D; Bohbot E; Dranitzki Z; Shalit M; Tal Y
    J Allergy Clin Immunol Pract; 2016; 4(5):1000-2. PubMed ID: 27329468
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful Treatment of TAFRO Syndrome, a Variant of Multicentric Castleman's Disease, with Cyclosporine A: Possible Pathogenetic Contribution of Interleukin-2.
    Konishi Y; Takahashi S; Nishi K; Sakamaki T; Mitani S; Kaneko H; Mizutani C; Ukyo N; Hirata H; Tsudo M
    Tohoku J Exp Med; 2015 Aug; 236(4):289-95. PubMed ID: 26250536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful tocilizumab treatment in a patient with human herpesvirus 8-positive and human immunodeficiency virus-negative multicentric Castleman's disease of plasma cell type nonresponsive to rituximab-CVP therapy.
    Műzes G; Sipos F; Csomor J; Sréter L
    APMIS; 2013 Jul; 121(7):668-74. PubMed ID: 23163599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization.
    Wong JT; Ling M; Patil S; Banerji A; Long A
    J Allergy Clin Immunol Pract; 2014; 2(1):40-5. PubMed ID: 24565767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castleman's disease.
    Angenendt L; Kerkhoff A; Wiebe S; Mikesch JH; Rudat A; Wötzel F; Wenning C; Schliemann C; Kessler T; Schäfers M; Wardelmann E; Stelljes M; Berdel WE
    Ann Hematol; 2015 Jul; 94(7):1241-3. PubMed ID: 25791243
    [No Abstract]   [Full Text] [Related]  

  • 18. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.
    Castells MC; Tennant NM; Sloane DE; Hsu FI; Barrett NA; Hong DI; Laidlaw TM; Legere HJ; Nallamshetty SN; Palis RI; Rao JJ; Berlin ST; Campos SM; Matulonis UA
    J Allergy Clin Immunol; 2008 Sep; 122(3):574-80. PubMed ID: 18502492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of aggressive HIV-associated multicentric Castleman's disease: a case report.
    Flejsierowicz M; Ahmed MS; Kotov P; Cheng YC
    WMJ; 2008 Jul; 107(4):191-4. PubMed ID: 18702436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypersensitivity to biological agents-updated diagnosis, management, and treatment.
    Galvão VR; Castells MC
    J Allergy Clin Immunol Pract; 2015; 3(2):175-85; quiz 186. PubMed ID: 25754718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.